Page last updated: 2024-10-22

alosetron and Obesity

alosetron has been researched along with Obesity in 2 studies

alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
France, M1
Skorich, E1
Kadrofske, M1
Swain, GM1
Galligan, JJ1
Camilleri, M1

Reviews

1 review available for alosetron and Obesity

ArticleYear
Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
    Neurogastroenterology and motility, 2007, Volume: 19 Suppl 2

    Topics: Appetite Depressants; Carbolines; Cyclobutanes; Dyspepsia; Gastrointestinal Agents; Genetic Variatio

2007

Other Studies

1 other study available for alosetron and Obesity

ArticleYear
Sex-related differences in small intestinal transit and serotonin dynamics in high-fat-diet-induced obesity in mice.
    Experimental physiology, 2016, Volume: 101, Issue:1

    Topics: Animals; Carbolines; Diet, High-Fat; Female; Fluoxetine; Gastrointestinal Transit; Intestine, Small;

2016